Core Viewpoint - The newly revised "Regulations on the Implementation of the Drug Administration Law of the People's Republic of China" marks the first comprehensive revision in 23 years, aimed at enhancing the drug regulatory system and supporting high-quality development in the pharmaceutical industry. The regulations will take effect on May 15, 2026 [1]. Group 1: Regulatory Changes - Over 90% of the provisions in the revised regulations have been amended, shifting the regulatory focus from drug production and operation enterprises to drug marketing authorization holders, who are now required to establish robust quality assurance and pharmacovigilance systems [1][2]. - The regulations introduce a market exclusivity period for pediatric and rare disease medications, incentivizing innovation in special drug development to better meet clinical needs [2][3]. Group 2: Innovation and Market Exclusivity - The regulations provide a market exclusivity period of up to 2 years for new pediatric drugs and up to 7 years for rare disease treatments, contingent on the marketing authorization holder's commitment to ensure drug supply [2][3]. - This exclusivity is designed to encourage investment in biotechnology companies focused on rare diseases, preventing resource wastage and promoting differentiated competition in the market [3]. Group 3: Protection of Intellectual Property - The regulations strengthen the protection of innovators' rights by safeguarding undisclosed trial data and other information submitted by marketing authorization holders for up to 6 years, preventing unauthorized commercial use [4]. - The State Drug Administration plans to enhance drug regulatory reforms, support innovation, and improve the efficiency of drug review and approval processes to accelerate the availability of new drugs that meet public demand [4].

Core Viewpoint - The newly revised "Regulations on the Implementation of the Drug Administration Law of the People's Republic of China" aims to enhance drug regulation and innovation, with a focus on pediatric and rare disease medications, and will take effect on May 15, 2026 [1] Group 1: Regulatory Changes - The revised regulations represent the first comprehensive update since 2002, reflecting significant changes in drug research, production, distribution, and usage over the past 23 years [1] - The regulations introduce a market exclusivity period for pediatric and rare disease medications, providing up to 7 years of exclusivity for qualifying drugs, contingent on the commitment to ensure supply [2][3] - The regulations establish a data protection system for trial data related to new chemical entities, preventing unauthorized commercial use of undisclosed data [2] Group 2: Support for Innovation - The regulations emphasize support for drug development and innovation driven by clinical value, encouraging the research and creation of new drugs [1] - A breakthrough therapy designation and expedited registration processes are introduced to accelerate the approval of innovative drugs [3] Group 3: Quality and Safety Management - Drug marketing authorization holders are required to establish comprehensive quality assurance and pharmacovigilance systems, ensuring ongoing evaluation of drug quality throughout its lifecycle [3] - The regulations clarify the responsibilities of online drug sales platforms, mandating them to implement strict oversight and management of drug transactions [3] Group 4: Traditional Chinese Medicine (TCM) and Institutional Management - The regulations promote quality management standards for TCM production, encouraging local governments to develop relevant plans [4] - The management of medical institution preparations is strengthened, allowing for the formulation of pediatric medications and detailing the approval and usage processes [4]